Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 15/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 15/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3538051 | 1.00 | EPHX2 (0.41) | EPHX2HCRTR1HCRTR2MEN1KMT2A | |
| SCHEMBL3287508 | 0.84 | SMN1; SMN2 (0.44) | MEN1KMT2A | |
| SCHEMBL3288443 | 0.84 | SMN1; SMN2 (0.44) | MEN1KMT2A | |
| SCHEMBL3533543 | 0.80 | GRM1 (0.51) | HCRTR1HCRTR2GRM1 | |
| SCHEMBL3534880 | 0.80 | GRM1 (0.51) | HCRTR1HCRTR2GRM1 | |
| SCHEMBL5307391 | 0.72 | P2RX7 (0.53) | — | |
| SCHEMBL3569215 | 0.71 | CHRNB2 (0.55) | HCRTR1HCRTR2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL3573473 | 0.71 | CHRNB2 (0.55) | HCRTR1HCRTR2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL3573477 | 0.71 | CHRNB2 (0.55) | HCRTR1HCRTR2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL3287512 | 0.71 | ALDH1A1 (0.34) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546374-B2 | Amino-tetrazoles analogues and methods of use | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120329772-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2012-12-27 | — | — | US | disclosed |
| US-8217067-B2 | Antiinflammatory agents, antidepressants, analgesics, purinergic receptor antagonists; neurodegenerative diseases, spinal cord injuries; 1-(2,3-dichlorophenyl)-N-[(2-methylphenyl)methyl]-1H-tetraazol-5-amine | ABBOTT LABORATORIES (US) | 2012-07-10 | — | — | US | disclosed |
| US-7704997-B1 | Amino-tetrazole analogues and methods of use | ABBOTT LABORATORIES (US) | 2010-04-27 | — | — | US | disclosed |
| US-20070049584-A1 | Amino-tetrazoles analogues and methods of use | ABBVIE INC. | 2007-03-01 | — | — | US | disclosed |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | ABBVIE INC. | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329772-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | P2RX7, P2RX2, P2RX5 | EPHX2 1385/4885HCRTR1 302/4885HCRTR2 349/4885 |
| US-20070049584-A1 | Amino-tetrazoles analogues and methods of use | P2RX7, P2RX2, P2RX5 | EPHX2 1385/4885HCRTR1 302/4885HCRTR2 349/4885 |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | P2RX7, P2RX2, P2RX3 | EPHX2 1355/4885HCRTR1 290/4885HCRTR2 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.